Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

233.84USD
23 Feb 2018
Change (% chg)

$7.10 (+3.13%)
Prev Close
$226.74
Open
$228.50
Day's High
$233.92
Day's Low
$226.62
Volume
536,170
Avg. Vol
866,915
52-wk High
$248.97
52-wk Low
$158.02

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $34,374.48
Shares Outstanding(Mil.): 147.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.28 16.59
EPS (TTM): -- -- --
ROI: -- 9.69 35.07
ROE: -- 14.25 17.79

BRIEF-Illumina Q4 GAAP Earnings Per Share $0.46

* ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2017

Jan 30 2018

BRIEF-Illumina Awarded $26.7 Mln In Patent Suit Against Ariosa Diagnostics

* ILLUMINA AWARDED $26.7M IN PATENT SUIT AGAINST ARIOSA DIAGNOSTICS, INC.

Jan 26 2018

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

Jan 25 2018

UPDATE 1-Illumina wins $26.7 mln in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

Jan 25 2018

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

Jan 25 2018

BRIEF-Premaitha Health Says Secured Right To Appeal First Instance Judgment

* HAS SECURED RIGHT TO APPEAL A FIRST INSTANCE JUDGMENT IN ITS ONGOING LITIGATION WITH ILLUMINA INC. AND OTHERS

Jan 24 2018

Cornell must arbitrate claims it was duped into Illumina patent deal: judge

A federal magistrate judge on Friday ruled Cornell University must arbitrate its claim that a former co-plaintiff duped it into settling a gene-sequencing patent dispute with Illumina Inc.

Jan 19 2018

BRIEF-Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018

* ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018

Jan 11 2018

BRIEF-Guangzhou Kingmed Diagnostics' Unit Signs Agreement With U.S. company Illumina

Jan 8 Guangzhou Kingmed Diagnostics Group Co Ltd :

Jan 08 2018

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT

Dec 27 2017

Earnings vs. Estimates